AR133953A1 - Inhibidores del factor b del complemento y usos de los mismos - Google Patents
Inhibidores del factor b del complemento y usos de los mismosInfo
- Publication number
- AR133953A1 AR133953A1 ARP240102601A ARP240102601A AR133953A1 AR 133953 A1 AR133953 A1 AR 133953A1 AR P240102601 A ARP240102601 A AR P240102601A AR P240102601 A ARP240102601 A AR P240102601A AR 133953 A1 AR133953 A1 AR 133953A1
- Authority
- AR
- Argentina
- Prior art keywords
- complement factor
- inhibitors
- compounds
- useful
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan en la presente compuestos de la fórmula (1) y composiciones farmacéuticas de los mismos útiles para tratar enfermedades o trastornos mediados por el factor B del complemento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363586620P | 2023-09-29 | 2023-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133953A1 true AR133953A1 (es) | 2025-11-19 |
Family
ID=93284092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240102601A AR133953A1 (es) | 2023-09-29 | 2024-09-26 | Inhibidores del factor b del complemento y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4784563A1 (es) |
| KR (1) | KR20260079630A (es) |
| CN (1) | CN121925409A (es) |
| AR (1) | AR133953A1 (es) |
| AU (1) | AU2024351332A1 (es) |
| CO (1) | CO2026003568A2 (es) |
| DO (1) | DOP2026000079A (es) |
| IL (1) | IL326819A (es) |
| MX (1) | MX2026003030A (es) |
| TW (1) | TW202515541A (es) |
| UY (1) | UY40901A (es) |
| WO (1) | WO2025068951A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026008072A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂在制备治疗或预防pnh药物中的用途 |
| WO2026008073A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂的剂量组合物 |
| WO2026008074A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂的晶型、其制备方法及用途 |
| WO2026069246A1 (en) * | 2024-09-30 | 2026-04-02 | Novartis Ag | Complement factor b inhibitors and uses thereof |
| WO2026130552A1 (zh) * | 2024-12-20 | 2026-06-25 | 南京正大天晴制药有限公司 | 补体因子B抑制剂在制备治疗或预防IgA肾病或其相关的疾病或病症的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| EP4650351A1 (en) * | 2023-01-09 | 2025-11-19 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor of complement factor b |
-
2024
- 2024-09-26 TW TW113136616A patent/TW202515541A/zh unknown
- 2024-09-26 WO PCT/IB2024/059431 patent/WO2025068951A1/en not_active Ceased
- 2024-09-26 UY UY0001040901A patent/UY40901A/es unknown
- 2024-09-26 AU AU2024351332A patent/AU2024351332A1/en active Pending
- 2024-09-26 CN CN202480062512.2A patent/CN121925409A/zh active Pending
- 2024-09-26 IL IL326819A patent/IL326819A/en unknown
- 2024-09-26 EP EP24798292.9A patent/EP4784563A1/en active Pending
- 2024-09-26 KR KR1020267012669A patent/KR20260079630A/ko active Pending
- 2024-09-26 AR ARP240102601A patent/AR133953A1/es unknown
-
2026
- 2026-03-11 MX MX2026003030A patent/MX2026003030A/es unknown
- 2026-03-24 DO DO2026000079A patent/DOP2026000079A/es unknown
- 2026-03-24 CO CONC2026/0003568A patent/CO2026003568A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121925409A (zh) | 2026-04-24 |
| UY40901A (es) | 2025-04-11 |
| CO2026003568A2 (es) | 2026-06-19 |
| KR20260079630A (ko) | 2026-06-02 |
| MX2026003030A (es) | 2026-05-04 |
| DOP2026000079A (es) | 2026-04-30 |
| EP4784563A1 (en) | 2026-08-05 |
| IL326819A (en) | 2026-04-01 |
| TW202515541A (zh) | 2025-04-16 |
| WO2025068951A1 (en) | 2025-04-03 |
| AU2024351332A1 (en) | 2026-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40204A (es) | Inhibidores del Factor B del Complemento y Usos de los mismos | |
| DOP2026000079A (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| DOP2024000142A (es) | Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CL2020002511A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CO2021015318A2 (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| CL2025000629A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| DOP2021000062A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| CO2025003090A2 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| CL2025000272A1 (es) | Derivados de arilo tricíclico y composiciones y métodos de los mismos | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| UY39681A (es) | Derivados de ciclobutilo 1,3–sustituidos y sus usos | |
| ECSP21010874A (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
| AR127127A1 (es) | NUEVOS DERIVADOS DE PIRIDODIAZEPINAS COMO PAM DE GABAA g1 | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 |